13/11/201826/01/2024 Helix BioPharma Corp. Provides Strategic Update on L-DOS47 Clinical Program admin 0 Comments
01/11/201826/01/2024 Helix BioPharma Corp. to initiate new L-DOS47 clinical program in pancreatic cancer admin 0 Comments
10/10/201826/01/2024 Helix BioPharma Corp. and Moffitt Cancer Center extend collaboration on immunotherapy, including study of L-DOS47 with PD-1/PD-L1 inhibitors admin 0 Comments
13/09/201826/01/2024 Helix BioPharma Corp. Initiates Enrollment of the Second Last Cohort in U.S. Combination Treatment Study of Its Lung Cancer Drug Candidate L-DOS47 admin 0 Comments
12/09/201826/01/2024 Helix BioPharma Corp. collaborator ProMab Biotechnologies Publishes Paper on Multiple Myeloma CAR-T admin 0 Comments
04/09/201826/01/2024 Helix BioPharma Corp. collaborator ProMab Biotechnologies to present at the CAR-TCR Summit 2018 in Boston admin 0 Comments